Eyconis to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceREDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its management team will participate in one-on-one investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14–16, 2026, in New York City.
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration PatientsFirst patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection
